Medmira (TSE:MIR) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MedMira Inc. has reported progress in expanding its market presence and securing regulatory approvals. The company received FDA approval for its HIV test and is awaiting further approvals for its Syphilis test in Canada. Additionally, MedMira has signed significant distribution agreements in the US to enhance its product reach.
For further insights into TSE:MIR stock, check out TipRanks’ Stock Analysis page.